CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial

Autor: Laterre, Pierre-François, Colin, Gwenhael, Dequin, Pierre-François, Dugernier, Thierry, Boulain, Thierry, Azeredo da Silveira, Samareh, Lajaunias, Frédéric, Perez, Antonio, François, Bruno
Zdroj: In The Lancet Infectious Diseases June 2019 19(6):620-630
Databáze: ScienceDirect